Logo
x

Search

Subscribe Now

Innovent

Innovent Reports the NMPA’s NDA Acceptance of Mazdutide to Treat Type 2 Diabetes

Innovent Reports the NMPA’s NDA Acceptance of Mazdutide to Treat Type 2 Diabetes

  • August 1, 2024
PharmaShots Weekly Snapshots (July 22 – July 26, 2024)

PharmaShots Weekly Snapshots (July 22 – July 26, 2024)

  • July 26, 2024
Innovent Reports Data from the P-III (DREAMS-1) Study of Mazdutide to Treat Type 2 Diabetes in Chinese Patients

Innovent Reports Data from the P-III (DREAMS-1) Study of Mazdutide to Treat Type 2 Diabetes in Chinese Patients

  • July 22, 2024
Innovent’s IBI343 Gains the US FDA’s Fast Track Designation to Treat Pancreatic Cancer

Innovent’s IBI343 Gains the US FDA’s Fast Track Designation to Treat Pancreatic Cancer

  • June 13, 2024
Innovent Reports the P-III (CLEAR-1) Study Data of Picankibart for Treating Plaque Psoriasis in Chinese Patients

Innovent Reports the P-III (CLEAR-1) Study Data of Picankibart for Treating Plaque Psoriasis in Chinese Patients

  • May 28, 2024
Innovent Reports the NMPA’s NDA Acceptance of IBI311 for Treating Thyroid Eye Disease

Innovent Reports the NMPA’s NDA Acceptance of IBI311 for Treating Thyroid Eye Disease

  • May 21, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.